Can-Fite BioPharma Ltd. (CANF.TA)
CANF.TA Stock Price Chart
Explore Can-Fite BioPharma Ltd. interactive price chart. Choose custom timeframes to analyze CANF.TA price movements and trends.
CANF.TA Company Profile
Discover essential business fundamentals and corporate details for Can-Fite BioPharma Ltd. (CANF.TA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Oct 2005
Employees
5.00
Website
https://www.canfite.comCEO
Motti Farbstein
Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
CANF.TA Financial Timeline
Browse a chronological timeline of Can-Fite BioPharma Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Apr 2026
Upcoming earnings on 28 Aug 2025
Earnings released on 14 Apr 2025
EPS came in at -ILA 0.00 surpassing the estimated -ILA 0.00 by +20.62%, while revenue for the quarter reached ILA 728.73K, missing expectations by -33.33%.
Earnings released on 28 Mar 2025
Earnings released on 28 Nov 2024
EPS came in at -ILA 0.00 matching the estimated -ILA 0.00, while revenue for the quarter reached ILA 1.12M, beating expectations by +646.32%.
Earnings released on 28 Aug 2024
EPS came in at -ILA 0.00 surpassing the estimated -ILA 1.50 by +99.72%, while revenue for the quarter reached ILA 377.91K, missing expectations by -31.29%.
Earnings released on 26 Jun 2024
EPS came in at -ILA 0.00 surpassing the estimated -ILA 1.50 by +99.71%, while revenue for the quarter reached ILA 1.11M, beating expectations by +98.07%.
Earnings released on 28 Mar 2024
EPS came in at -ILA 0.04 surpassing the estimated -ILA 0.97 by +95.88%, while revenue for the quarter reached ILA 557.99K, beating expectations by +55.00%.
Earnings released on 30 Nov 2023
EPS came in at -ILA 0.01 surpassing the estimated -ILA 1.64 by +99.66%, while revenue for the quarter reached ILA 750.72K, missing expectations by -1.75%.
Earnings released on 31 Aug 2023
EPS came in at -ILA 0.01 surpassing the estimated -ILA 1.59 by +99.68%, while revenue for the quarter reached ILA 721.48K, missing expectations by -2.89%.
Earnings released on 1 Jun 2023
EPS came in at -ILA 0.01 surpassing the estimated -ILA 0.01 by +14.91%, while revenue for the quarter reached ILA 701.62K.
Earnings released on 27 Mar 2023
EPS came in at -ILA 0.01, while revenue for the quarter reached ILA 679.02K.
Earnings released on 25 Nov 2022
EPS came in at -ILA 0.01 surpassing the estimated -ILA 0.01 by +1.03%, while revenue for the quarter reached ILA 721.60K, missing expectations by -32.50%.
Earnings released on 30 Jun 2022
EPS came in at -ILA 0.01 falling short of the estimated -ILA 0.01 by -21.40%, while revenue for the quarter reached ILA 710.08K, missing expectations by -18.76%.
Earnings released on 31 Mar 2022
EPS came in at -ILA 0.01 surpassing the estimated -ILA 0.01 by +32.82%, while revenue for the quarter reached ILA 654.49K, beating expectations by +53.45%.
Earnings released on 31 Dec 2021
EPS came in at -ILA 0.02, while revenue for the quarter reached ILA 633.42K.
Earnings released on 30 Sept 2021
EPS came in at -ILA 0.02 falling short of the estimated -ILA 0.02 by -13.40%, while revenue for the quarter reached ILA 807.63K, missing expectations by -2.53%.
Earnings released on 30 Jun 2021
EPS came in at -ILA 0.02, while revenue for the quarter reached ILA 815.23K.
Earnings released on 31 Mar 2021
EPS came in at -ILA 0.01, while revenue for the quarter reached ILA 492.71K.
Earnings released on 31 Dec 2020
EPS came in at -ILA 0.03, while revenue for the quarter reached ILA 481.91K.
Earnings released on 30 Sept 2020
EPS came in at -ILA 0.02, while revenue for the quarter reached ILA 723.05K.
CANF.TA Stock Performance
Access detailed CANF.TA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.